Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Interventions: Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 13
States / cities: Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more

Conditions: Renal Impairment
Interventions: tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Chronic Nociceptive Pain, Neuropathic Pain, Non-cancer Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Epithelial Ovarian Carcinoma
Interventions: Metformin, Paclitaxel, Carboplatin; Drug
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Peanut Allergy
Interventions: AR101 - Peanut protein capsule; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 26 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Atherosclerosis
Interventions: SB-480848, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 28
States / cities: Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more

Conditions: Periodontal Diseases
Interventions: BioXclude™; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Rebif® new formulation (RNF); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more

Conditions: Pain Management, Postoperative Pain
Interventions: PCDD Generation 1 system; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Oropharyngeal Cancer, Human Papilloma Virus
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gingivitis, Dental Plaque
Interventions: Next Science OTC Oral Rinse with Essential Oils, OTC Oral Rinse Control; Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery; Biological · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cannabis Use, Cannabis Intoxication, Cannabis Use Disorder
Interventions: Biologic testing for THC; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Sarcoidosis
Interventions: OATD-01, Placebo; Drug
Lead sponsor: Molecure S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Acute Lymphobkastic Leukemia, Medication Adherence
Interventions: Educational Website, #AYAOSM; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 15 Years to 25 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 4
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Facial Neuropathy
Interventions: Lamotrigine, Placebo (for Lamotrigine); Drug
Lead sponsor: Pain and Analgesia Imaging and Neuroscience Group; Other
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Interventions: MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole; Drug
Lead sponsor: Metagen Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Naples, Florida • Boston, Massachusetts • New York, New York

Conditions: Acne Vulgaris
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Integrative Skin Science and Research; Industry
Eligibility: 13 Years to 45 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Parkinson Disease
Interventions: PRIM-DJ2727, Placebo oral capsule; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 55 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
Interventions: exercise intervention, amifostine trihydrate, therapeutic dietary intervention; Behavioral · Drug · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tendinopathy
Interventions: secukinumab, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • La Mesa, California • Clearwater, Florida + 2 more

Conditions: Diabetes Mellitus, With Complications
Interventions: Effect of Pulsatile IV Insulin on diabetic neuropathy; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 20 Years to 90 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: IW-3718, placebo, Standard-dose PPIs QD; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 93
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more

Conditions: Non-small Cell Lung Cancer
Interventions: Rociletinib; Drug
Lead sponsor: Clovis Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 41
States / cities: Alhambra, California • Bakersfield, California • Fullerton, California + 36 more

Search by objective public record fields.

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone

Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

SB-480848 In Subjects With Coronary Heart Disease

Addition of Dehydrated Human Amnion-Chorion Membrane During Scaling and Root Planing

Oral Cladribine in Early Multiple Sclerosis (MS)

PCDD Generation 1 Oral Liquid Acetaminophen Delivery Evaluation

Men and Women Offering Understanding of Throat HPV

Next Science Antimicrobial Mouth Rinse Study

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Study of an Oral Fluid Testing Approach

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

The AYA Oncology Self-care Movement

Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)

Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris

Study of the Fecal Microbiome in Patients With Parkinson's Disease

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer